# Phase 2 Study of Standard Chemotherapy With Trastuzumab, Plus or Minus Pertuzumab, for Pre-treated Metastatic Breast Cancer

> **NCT02229149** · PHASE2 · TERMINATED · sponsor: **US Oncology Research** · enrollment: 33 (actual)

## Conditions studied

- Breast Neoplasms
- Malignant Tumor of the Breast

## Interventions

- **DRUG:** Trastuzumab
- **DRUG:** Pertuzumab
- **DRUG:** Vinorelbine, Paclitaxel, Nab-Paclitaxel , Docetaxel, Capecitabine

## Key facts

- **NCT ID:** NCT02229149
- **Lead sponsor:** US Oncology Research
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2014-12
- **Primary completion:** 2022-01
- **Final completion:** 2022-01
- **Target enrollment:** 33 (ACTUAL)
- **Why stopped:** per Sponsor request
- **Last updated:** 2022-12-02

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02229149

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02229149, "Phase 2 Study of Standard Chemotherapy With Trastuzumab, Plus or Minus Pertuzumab, for Pre-treated Metastatic Breast Cancer". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT02229149. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*